Rimegepant, sold under the brand name Nurtec ODT, is a medication for the treatment of an acute migraine with or without aura in adults. It is not used prophylactically.
Taken by mouth to dissolve on or under the tongue, rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It is not a narcotic and has no addictive potential; thus it is not designated as a controlled substance.[medical citation needed] It works by blocking CGRP receptors.
Approved for use in the United States in February 2020, rimegepant is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.